MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00467-021-05111-x

Медицинская библиотека · Pediatric nephrology (Berlin, Germany) · 2021

Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?

Ozsurekci Yasemin, Oygar Pembe Derin, Gürlevik Sibel Laçinel, Kesici Selman, Ozen Seza, Kurt Sukur Eda Didem, Gülhan Bora, Topaloglu Rezan, Bayrakci Benan, Cengiz Ali Bülent

Клиническое исследованиеСтатьяПеревод в очереди

Аннотация

BACKGROUND

The rising number of infections due to Severe Acute Respiratory Syndrome Coronavirus-2 (popularly known as COVID-19) has brought to the fore new antiviral drugs as possible treatments, including favipiravir. However, there is currently no data regarding the safety of this drug in patients with kidney impairment. The aim of this paper, therefore, is to share our experience of the use of favipiravir in pediatric patients affected by COVID-19 with any degree of kidney impairment.

METHODS

The study enrolled pediatric patients aged under 18 years and confirmed as suffering from COVID-19 and multisystem inflammatory syndrome in children (MIS-C) with any degree of kidney injury, who were treated with favipiravir at the time of admission.

RESULTS

Out of a total of 11 patients, 7 were diagnosed with MIS-C and 4 with severe COVID-19. The median age of the cases was 15.45 (9-17.8) years and the male/female ratio was 7/4. At the time of admission, the median serum creatinine level was 1.1 mg/dl. Nine patients were treated with favipiravir for 5 days, and 2 patients for 5 days followed by remdesivir for 5-10 days despite kidney injury at the time of admission. Seven patients underwent plasma exchange for MIS-C while 2 severely affected cases underwent continuous kidney replacement therapy (CKRT) as well. One severe COVID-19 patient received plasma exchange as well as CKRT. Serum creatinine values returned to normal in mean 3.07 days.

CONCLUSIONS

Favipiravir seems a suitable therapeutic option in patients affected by COVID-19 with kidney injury without a need for dose adjustment.

Для цитирования: Ozsurekci Yasemin, Oygar Pembe Derin, Gürlevik Sibel Laçinel, Kesici Selman, Ozen Seza, Kurt Sukur Eda Didem, Gülhan Bora, Topaloglu Rezan, Bayrakci Benan, Cengiz Ali Bülent. Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?. Pediatric nephrology (Berlin, Germany). 2021. DOI: 10.1007/s00467-021-05111-x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.